Research programme: T-cell engagers-based therapeutics - Amunix
Alternative Names: EGFR-XPAT - Amunix; XTENylated protease-activated T Cell engagers based therapeutics - AmunixLatest Information Update: 28 Aug 2023
At a glance
- Originator Amunix
- Class Antineoplastics; Peptides; Recombinant fusion proteins
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 17 Jan 2022 Amunix has been acquired by Sanofi
- 22 Jul 2019 Early research in Cancer in USA (Parenteral) before July 2019 (Amunix pipeline, July 2019)